Morrisville, NC – Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies to cure cancer, announced today that it will present an update on IB-T101, its lead CAR-T program targeting CD70, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
IB-T101 is an autologous CAR-T therapy developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The program is powered by OUTLAST™, Inceptor’s proprietary platform designed to enhance T cell persistence and performance in the solid tumor microenvironment.
The ASCO poster will highlight key preclinical data supporting the mechanism of action for IB-T101, along with details of the ongoing Phase 1 trial evaluating its safety and feasibility in patients with CD70-positive ccRCC.
ASCO 2025 Presentation Details:
Title: A Phase 1, First-in-Human Study of IB-T101, an OUTLAST™ CAR-T Product for the Treatment of CD70-Positive Clear Cell Renal Cell Carcinoma
Date: Monday, June 2, 2025
Time: 1:30–4:30 PM CT
Location: Poster Board #319a
Presenter: Matthias Schroff, PhD, Chief Executive Officer, Inceptor Bio
“This presentation marks an important milestone for IB-T101 and the OUTLAST™ platform,” said Matthias Schroff, PhD, CEO of Inceptor Bio. “We’ve built this program to tackle the core challenge in solid tumors – getting T cells to persist and perform in hostile environments. OUTLAST™ gives us the foundation to do that. We’re excited to share the rationale behind our approach and the Phase 1 trial design with the oncology community at ASCO 2025.”
About Inceptor Bio
Inceptor Bio, founded in May 2020 and headquartered in Research Triangle Park, NC, is dedicated to advancing next-generation cell and gene therapies to cure cancer. The company’s proprietary OUTLAST™ platform reprograms T cells to maintain stemness and effector function, addressing the unique challenges of treating solid tumors. Inceptor’s lead program, IB-T101, targets CD70 in clear cell Renal Cell Carcinoma (ccRCC) and represents a potentially best-in-class therapy. With a strong leadership team and strategic partnerships, Inceptor Bio is committed to advancing a pipeline of cutting-edge therapies to improve outcomes for patients with limited treatment options globally.
